Here’s the American English translation:
Theriva Biologics, a clinical-stage company focused on developing innovative cancer treatments, has published its financial results for the third quarter ending September 30, 2025. As of that date, the company reported cash and cash equivalents of $7.5 million, which increased to $15.5 million following recent capital raises conducted up to November 10, 2025. This strong financial position will allow Theriva to maintain its liquidity until the first quarter of 2027, which is crucial for the next phases of its clinical trials and the development of its product pipeline.
Steven A. Shallcross, CEO of Theriva Biologics, highlighted the success in generating clinical data, particularly concerning its flagship product VCN-01, an oncolytic adenovirus. At the ESMO 2025 conference, the company presented promising results from the Phase 2b clinical trial, known as VIRAGE, where VCN-01 was combined with standard chemotherapy in patients diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC). Shallcross emphasized that the results have been encouraging in terms of overall survival and duration of response in patients receiving this therapeutic combination.
Theriva also plans to collaborate with regulatory authorities in Europe and the United States to establish a Phase 3 study protocol for VCN-01, alongside gemcitabine/nab-paclitaxel, as a first-line treatment for metastatic PDAC. Additionally, the company is designing clinical trials for VCN-12, another of its therapeutic candidates, aimed at treating retinoblastoma, a rare pediatric disease.
From a financial perspective, the company reported a reduction in general and administrative expenses, which decreased to $1.9 million compared to $2.3 million in the same quarter of the previous year. This decrease is attributed to an adjustment in compensation costs and other operational expenses. Meanwhile, research and development expenditures also showed a slight decrease, reaching $2.6 million compared to $2.7 million in the third quarter of 2024.
With a robust financial foundation and significant clinical advances, Theriva Biologics is well-positioned to tackle new challenges in its research and the development of innovative cancer therapies, aiming to address areas of high medical need and improve the quality of life for patients.
Source: MiMub in Spanish
